“At~6%,canceristhe3rdbiggestcauseofmortalityinIndiaafterCardiovascularandRespiratorydiseases.AlthoughthecancerincidenceratepermillionofpopulationisrelativelysmallercomparedtothedevelopedcountrieslikeUSA&UK,itmightbejusttipoficebergwithlimitedaccesstodiagnosisandtreatmentformajorityofthepopulation.Almost90%ofcomprehensivecancertreatmentcentresareinmajorcities,while~70%ofthepopulationisintheruralareas.Theothermajorissue-limitedaccesstoscreeninganddiagnosis-isprimarilybecauseoflowpenetrationofdiagnosticimagingequipmentlikeCT,MRI,Mammography,PETCTetc.Morethan50%patientsarediagnosedatarelativelyadvancedstage,witha5yearsurvivalraterangingbetweenamere10to27%.Inthisreport,wehavelookedintothecurrentstatusoftopcancersinmenandwomen(oralandlunginmen,breastandcervixinwomen),withanemphasisonscreening,diagnosisandtreatmentstages.We’veevaluatedthemainbarriersinthesestagesandwhattheplayofMedTechandHealthTechcompaniescanbe,inhelpingimproveoutcomesbymakingthetechnologiesmoreaccessibleandaffordable.Wehaveespeciallylookedatboth,theexistingaswellasemergingtechnologiesinscreeninganddiagnosisareas,asthebiggestimpactinoutcomewillcomefromincreasedaccesstothesetechnologiesenablingearlydetection.Forexample,earlydetectionofbreastcancercanleadtoasigni?cantlyhigher5yearsurvivalrate~90%comparedtocurrent~22%.Wealsoevaluatedthevolumegrowthinoncologyproceduresindiagnosis,surgery,chemotherapyandradiationtherapyto~15%”?PGALabs|03CancerincidenceCancerscreeningCancerincidenceCancerscreening心心?ThetotalnumberofnewcancercasesinIndiaareexpectedtoreach~1.5millionby2025,growingataCompoundAnnualGrowthRate(CAGR)of~2%from2020to2025?Amongwomen,breastandcervicalcancershavethehighestincidencerates.Inmen,theincidenceoforalandlungcancersisrelativelyhigherthanothercancers?India’sage-standardizedcancerincidencecases(permillion)stoodat~97,lowerduetotheavailabilityofalternatetherapiesandverylowdiagnosisrate?Morethan50%ofcancercasesarediagnosedatadvancedstagesinIndia,whichifdetectedearlier,canincreasesurvivalratesby~50-80%?Forbreastcancer,~50%ofthecasesatdiagnosedatStage3;latestagesurvivalis~22%,whereasearlystagesurvivalis~90%?Inthecaseoflungcancer,~90%ofthecasesarediagnosedatadvancestages,wherethesurvivalratedropsto~10%.Forcervicalandoralcancers,diagnosisintheadvancedstagesstoodat~70%,withthelatestagesurvivalratesbeing~10%and~27%respectively?Lackofawarenessandaccessibility,lowsensitivity,discomfortandhighcostsarethemajorreasonsbehindthevastmajorityofeligiblepeoplenotundergoingcancerscreening?Propensitytovoluntarilyoptforcancerscreeningtestsislowinconsumersduetolackofawarenessofrelevanttests?Riskassessmenttestsforcancers,whichhavehigheraccuracyandaremorecomplexthanbasicscreeningtests,aretooexpensiveforalargechunkofthepopulation?PGALabs|04心心?The?TheNationalCancerControlProgramme(2004-05)hasbeencornerstoneforpolicy-makinginthe?eldofoncologyinIndia?Production-LinkedIncentiveSchemeof2020hadatotal?nancialoutlayof~$456Mforpromotingdomesticmanufacturingofmedicaldevicesacross4segmentsofmedicaldevices?Somemajorinitiativesbystategovernmentsinclude-medicaldeviceparks(TamilNadu,Punjab,UttarPradesh),aimedatprovidingaboosttomedicalmanufacturers,andcancerhospitals(Assam)?Innovationsincancerdiagnosticsforearlydetectionandscreeningisontheriseglobally,withimagingtechnologyadvancingmulti-fold?Start-upslikeNiramai(India),Vayyar(Israel)andEndomag(England)haveusedadvancedtechnologytomakebreastcancerscreeninganddetectionmoreaffordableandaccurate?Newcancercaremodelsrevolvearoundhomecare,treatmentwork?owmanagement,personalizedcancercare,affordabilityetc.RecenttrendsandinnovationsGovernmentinitiatives1.3CAGR~2%Totalnumberofnewcancercasesareexpectedto1.3CAGR~2%Totalnumberofnewcancercasesareexpectedtoreach1.5millionby2025Incidenceofcancer(2020-25,inM)1.52020E2025PCancercases心心Cancercasesareexpectedtoincrease~15%by2025;Breast&CervicalcancerinwomenandOral&Lungcancerinmenaremostprevalentamongallcancers520521020518950355982713972HigherincidenceofcanceramongwomenisofBreast(~205K)&Cervix(~75K)andamongmenisofOralcavity(~139K)andLung(~72K)520521020518950355982713972Incidenceofcancer(2020,inK)818OthersincludecancerOthersincludecancerofdigestivesystem,urinarysystem,endocrinesystem,leukaemia,lymphoma,brain,eye,genital(exceptbreast&cervix),respiratory(exceptlung),skin,bones&joints,andsofttissue4637575754637575OtherBreastOralcavity&LungCervixOtherpharynxMenWomenNote(s):2020incidencerateisestimatedand2025dataisprojectedSource(s):NationalCancerRegistryProgramme,India(2020report),Secondaryresearch,PGALabsanalysis?PGALabs|05Stageofdiagnosis–~50%arediagnosedatStage3Latestagesurvival–22%90% BreastCancerLungCancerStageofdiagnosis–~90%arediagnosedatadvancedstageLatestagesurvival–Earlystagesurvival–10%OralCancerStageofdiagnosis–~50%arediagnosedatStage3Latestagesurvival–22%90% BreastCancerLungCancerStageofdiagnosis–~90%arediagnosedatadvancedstageLatestagesurvival–Earlystagesurvival–10%OralCancerCancerDiagnosis心心Morethan50%ofcancercasesarediagnosedatadvancedstages;earlydetectioncanincreasesurvivalratesby50-80%inthecountryEarlystageEarlystagesurvival–CervicalcancerCervicalcancerStageofdiagnosis–~70%arediagnosedatStage310%Latestage10%survival–92%Earlystage92%survival–Note(s):Survivalratesarefor5-yearspostdiagnosisSource(s):Datarcancergenetics(2021),Researcharticles,Secondaryresearch,PGAlabsanalysis90%90%Stageofdiagnosis–~70%arediagnosedatStage3LatestageLatestagesurvival–survival–?PGALabs|06Lackofawareness,accessibilityandhighcostaresomeofthekeyfactorsforhinderancetocancerscrLackofawareness,accessibilityandhighcostaresomeofthekeyfactorsforhinderancetocancerscreeningLackofawarenessAccessibilityLowsensitivityDiscomfortHighcost?Peopleareunawareofscreeningprocedures&theirimportanceindetectingearly-stagecancer?MedicalequipmentissparselyavailableinTier3&Tier4citiesandruralareas?Peoplehavetotraveltolongdistancesinordertoaccesssaidcentres?Equipmentlikemammographsetc.havelowsensitivityinwomenwithdensebreasttissuetherebyrequiringmultipleadditionaltestswhichleadstoincreasedpatientnoncompliance?Manywomenexperiencediscomfortwhileundergoingscreeningtests?Testsforcon?rmeddiagnosis,progressionofcancerandcontinuousmonitoringisquiteexpensive-DomainexpertScreening心心Morethan98%ofpeoplewhoarerecommendedperiodicscreeninghaveneverbeenscreenedforcancerduetofactorslikelackofawareness,accessibilityandhighcosts98.4%16%98.7%13%99.0%10%Morethan98%ofpeopleeligiblefor98.4%16%98.7%13%99.0%10%Numberofpeoplescreenedforcancer(%,Agegroup)99.4%99.4%06%CervicalCervicalSource(s):NHFS5report(2019-21),Researcharticles,Cancerreports,Secondaryresearch,PGAlabsanalysis?PGALabs|07TestslikeHereditaryCancerRiskTestslikeHereditaryCancerRiskPro?ling(~$333)andCancerGenePanel(~$400)helpindiagnosingmultiplecancersClinicalexaminationsareusedtodetectoralcancer–therearenoproperscreeningtestsforthedetectionoforalcancerLowervaluetestscoveronlysomespeci?cantigentestswhicharenotprovenasde?nitivemarkersDiagnosticplayersPropensitytovoluntarilyoptforcancerscreeningtestsislowinconsumersduetolackofawarenessofrelevanttestsandexpensiveriskassessmenttestsCancerTypeTypicalScreeningTesttypeTestclassi?cationAveragepricerangeTest(USD)TestBreast?Mammogram?BreastUltrasound?OncoBRCA-Next?BRCA1&BRCA2ComprehensivePanel?BreastCancerMarker?TumourMarkerImagingCorerecommendation~23-28GenomicsequencingRiskassessment~267BloodHighriskrecommendation~13–27CervicalPAPSmearTestPathologyCorerecommendation~5–12HPVDNATestMolecularDiagnostics~7–27CervicalScreeningGenomicsequencing~20–40LungLowDoseCTImagingCorerecommendation~27–67LungCancerPro?lerGenomicsequencingRiskassessment~400LungCancerMarkerBloodHighriskrecommendation~33–53Oral?Colorectal??ColonoscopySigmoidoscopyImagingCorerecommended~27-80FecalOccultBloodTestPathology~3ProstrateBloodCorerecommended~7?ProstrateBloodCorerecommended~7TestSource(s):AmericanCancerSociety,Companywebsite(s),Secondaryresearch,PGALabsanalysis?PGALabs|08Biopsyneedle(coreneedle,?neneedleandbiopsygun)Mammography/PETCT/CT/MRI/Ultrasound/X-rayHOLOGICEmergingplayersLinearaccelerator(LINAC)RoboticSurgeryCatheter(PICCMedtronicACCURAYAbbottBrachytherapysystemLaparoscopicMetronicProtonbeamtherapysystemsFluorescenceimage-guidedsurgeryIrillicCarbonIontherapyCryosurgeryTOSHIBACyberknifeElectrosurgery,Lasersurgery&Video-assistedthoracicsurgery(VATS)EmergingplayersBiopsyneedle(coreneedle,?neneedleandbiopsygun)Mammography/PETCT/CT/MRI/Ultrasound/X-rayHOLOGICEmergingplayersLinearaccelerator(LINAC)RoboticSurgeryCatheter(PICCMedtronicACCURAYAbbottBrachytherapysystemLaparoscopicMetronicProtonbeamtherapysystemsFluorescenceimage-guidedsurgeryIrillicCarbonIontherapyCryosurgeryTOSHIBACyberknifeElectrosurgery,Lasersurgery&Video-assistedthoracicsurgery(VATS)EmergingplayersMedtronicPortIVCancercasesMarketlandscape:Screeninganddiagnosiscategoryhasseentheemergenceofnewentrants;mostcategoriesaredominatedbyMNCsScreening&DiagnosisRadiationtherapySurgeryChemotherapy&HormonalScreening&DiagnosisRadiationtherapySurgerytherapyMNCsNote(s):MNC-Multi-NationalCorporationMNCsSource(s):Secondaryresearch,PGALabsanalysis?PGALabs|0910%Women10%Men25%25%OralCervicalLungRadiationisgiveneitheraloneorasadjuvanttherapywithothertreatments75%75%Radiationisgiveneitheraloneorasadjuvant90%90%10%Women10%Men25%25%OralCervicalLungRadiationisgiveneitheraloneorasadjuvanttherapywithothertreatments75%75%Radiationisgiveneitheraloneorasadjuvant90%90%ComparativestudyMedicalinfrastructureforbothdiagnosisandtreatmentneedssigni?cantaug-mentationvs.othercountriesafteradjustingfordifferencesinincidencelevelsCountriesCancerincidencecases(permillion)(age-standardized)Mortalityrate(agestandardized)Capitalequipmentinstalled(permillion)(2020)CTMRIPETCTMammographyLINACUSUS362.2Recordedcasesareof86.342.640.4(2019)5.867.2UKUK319.9peoplereceivingtreatment&arelowerpeoplereceivingJapanJapan285.1duetoavailabilityofalternatetherapies&81.5115.757.44.733.897.1lowerdiagnosisrate63.15.3*2.7*0.4BrazilBrazil215.491.225.9RussiaRussia234.3113.713.9(2019)5.1(2019)1.3(2019) ComparativeunderpenetrationinIndiavs.othercountries(%,adjustedwithcancerincidence) US54%75%87%BrazilBrazil55%57%25%51%RussiaRussia8%28%26%LessincomparisonMoreincomparisonCancerpatientsrequiringradiation(in%)BreastBreastRadiationOtherstherapyRadiationOtherstreatmentsNote(s):representsestimatesSource(s):WHOreportonage-standardizedcancerrates(2020),OECDdatabase(2021),Secondaryresearch,PGALabsanalysis?PGALabs|10Tertiary(SH)LevelofCare*EndoflifecareTertiary(SH)LevelofCare*EndoflifecareCancercareTheprocessandlevelofcareofacancerpatientdependsuponthestageandtypeofcancerFollow-upFollow-up/survivorshipcarePreventionPalliativecareDiagnosisScreeningTreatmentSystemictherapyNuclearmedicineRadiotherapyNuclearmedicineSecondary(dh)Secondary(dh)&tertiary(sh)MedicalImagingMedicalImagingEndoscopyEndoscopySurgeryPathologyClinicallaboratoryPathologyClinicallaboratoryPrimarysecondary&tertiaryPalliativecareClinicalassessmentClinicalassessmentVaccinationNote(s):PrimaryincludesCommunityLevelhealthpostandHealthCentre,SecondaryincludesDirectHospital&tertiaryincludesSpecialisedHospitalSource(s):WHOreports,Secondaryresearch,PGALabsanalysis?PGALabs|11IDiagnosisSurgery RadiationTherapyNA~530M~1,170M~1,920MProcedureValue(US$)ProcedureVolumeTotalnumberofcycles~2.5M~0.45M~1.4M~0.6MIDiagnosisSurgery RadiationTherapyNA~530M~1,170M~1,920MProcedureValue(US$)ProcedureVolumeTotalnumberofcycles~2.5M~0.45M~1.4M~0.6M>15%>15%>15%10-15%sOncology心心Withincreasingawareness,affordabilityandinfrastructure,oncologyproceduresarelikelytowitnessa15%+growthOncologyChemotherapyChemotherapyProcedurevolumeProcedurevolumecomprisesofcasesofincidenceandprevalenceExpectedVolumeGrowthVolumegrowthrate10-15%>15%OncologyProcedureMix(2021)OthersOthers,20%Gynaecologic,20%Breast,20%Head&neck,40%Others,51%Others,51%Gynaecologic,14%Breast,15%Head&neck,20%DiagnosedSurgerySource(s):Primarydiscussions,PGALabsanalysisGrowthDriversIncreaseddiagnosisofcancerandriseinthenumberofscreeningfacilitiesRapidlyexpandingtechnicalinfrastructureinhealthcareresearchanddeliveryRiseinprivatehealthinsurancecoverage,especiallyafterthepandemicGovernmentinitiativestowardscancerawareness,supportandtreatment?PGALabs|1211Governmentinitiatives心心Governmentinitiatives:TheNationalCancerControlProgrammeandHealthMinister’sCancerPatientFundhavebeenthetopcancer-speci?cinitiativesinIndiaAreaofimpactInitiativeYearParticularsQualityofcareEvaluation&revisionofNationalCancerControlProgram2004-05Focusprimaryandsecondaryprevention,strengtheningofcancertreatmentfacilitiesandpalliativecareinterminalstagofcancerPradhanMantriJanArogyaYojana2018~435procedureswerede?nedforthetreatmentofcancer.Chemotherapy&Radiotherapypackages,alongwithsurgicaloncologywerecoveredAyushmanBharat-HealthandWellnessCenters(AB-HWC’s)2018Targetofsettingup~1.5lakhHealthandWellnessCenters(AB-HWC’s)byDecember2022;anoutlayof~US$8,530forthegrowthofIndia’spublichealthfacilities&infrastructureoveraperiodof5yearsAffordabilityHealthMinister’sCancerPatientFund2008-09HMCPFwasset-upforproviding?nancialassistancetothepoorpatientssufferingfromcancerin27RegionalCancerCenters(RCCs),withinRashtriyaArogyaNidhi(RAN)MRPreductionforanti-cancermedicine2019NationalPharmaceuticalPricingAuthorityputoutalistof390anti-cancernon-scheduledmedicineswith80%+MRPreductionsResearchCentreforIntegrativeOncology(CIO)2017CIOhasbeenestablishedasajointventureofAllIndiaInstituteofAyurveda(AIIA)andNationalInstituteofCancerPreventionandResearch(NICPR-ICMR)withtheintentionofcollaborativeresearchactivitiesincancerIndianCouncilofMedicalResearchatIndianInstitutesofTechnology2021ICMRcollaboratedwithIITstoestablish‘ICMRatIITs’bysettingupCentresofExcellence(CoE)forMake-in-IndiaproductdevelopmentandcommercializationinthemedicaldevicesanddiagnosticsspaceNote(s):MRP-MaximumRetailPriceSource(s):IBEF,InvestIndia,PressInformationBureau,Secondaryresearch,PGALabsanalysis?PGALabs|1322Governmentinitiatives心心Governmentinitiatives:MajorinitiativesbyStategovernmentsincludemedicaldeviceparks(TamilNadu,Punjab,UttarPradesh)andcancerhospitals(Assam)AreaofimpactInitiativeYearParticularsThereareThereare7majormanufacturingclustersformedicaldevicesinIndia–Gujarat,Maharashtra,Karnataka,AndhraPradesh,Telangana,TamilNadu&HaryanaInfrastructureandaccessibilityCancercarefacilitiesinMedicalCollegesunderPMSSY2019Cancertreatmentfacilitieswerecreated/plannedin13StateGovernmentMedicalCollegeswhichweretakenupforupgradationunderPMSSYNationalCancerInstitute(NCI)2019State-of-the-arttertiarycancercare-cum-researchInstituteconstructedattheAIIMSJhajjarcampusStrengtheningTertiaryCareofCancerScheme202119StateCancerInstitutes(SCIs)&20TertiaryCancerCentres(TCCCs)havebeenapprovedforenhancingfacilitiesfortertiarycareofcancer17CancerHospitalsinAssam2022AninitiativebyAssamCancerCareFoundation,ajointventureofGovernmentofAssamandTataTrusts,tobuildSouthAsia’slargestaffordablecancercarenetworkwith17Cancercarehospitalsspreadacrossthestate,7commissionedCancerCareInfrastructureinNorth-EastIndia2022InitiativetoestablishDedicatedServicesfortheManagementofPaediatric&AdultHaematolymphoidCancersinNorth-EastIndia,tobelocatedatBBCIGuwahatiManufacturingandproductionProductionLinkedIncentive(PLI)Scheme2020Total?nancialoutlayof$456Mforpromotingdomesticmanufacturingofmedicaldevicesacross4segmentsofmedicaldevices,includingcancercare/radiotherapymedicaldevicesMedicalDeviceParks2021Government(Central/State)approved/announcedmedicaldeviceparksinTamilNadu,UttarPradeshandPunjab.Privateinvestmenttoset-upamedicaldeviceparkinTelanganaNote(s):PMSSY-PradhanMantriSwasthyaSurakshaYojana;BBCI-Dr.BBorooahCancerInstituteSource(s):IBEF,InvestIndia,PressinformationBureau,PGALabsanalysis?PGALabs|14Recentinnovations心心Innovationsincancerdiagnosticsforearlydetectionandscreeningisthetrendwhichisontheriseglobally;imagingtechnologyisadvancingmulti-foldAreaofimpactStart-upYearLocationInnovationSolutionFunding(US$M)Cancerdiagnostics2016HighresolutionthermalsensingdeviceLow-cost,non-contact,non-invasiveandradiation-freebreastcancerdetectionanddiagnosistool~62004IngestibleimagingcapsulesCapsule-basedtestthatdetectsprecancerouspolyps,enablescolorectalcancerscreening~1102002SaaS-basedlesionmanagementsolutionsMedicalimagingsoftwareandservicesforclinicaltrialsusage~1202016AI-basedanalyticsanddiagnosisplatformAI-powereddiagnosticsforpathologyforaccurate,timelyandpersonalizedcancerdiagnosis~502011Mobile4-DimagingsensorSensor-basedtechnologyforeffectivescreeningofearly-stagebreastcancer~3002003Micro-ultrasoundimagingdeviceMicro-ultrasoundthatenableshigh-resolutionvisualizationandimagingofprostatecancerandbiopsies~25Tissuebiopsy2014High-de?nitionion-beamimagingMultiplexedion-beamimagingtechnologyisusedforanalysisoftissuebiopsies~20Surgicaloncology2012Guidancesystemforintracavityradio-guidedsurgeryMiniaturesurgicalgammaprobeusedforquicklocalizationofprostate,lung,cervicalcancers~30Tumourlocalizationendomag5只2007MagneticsensorsMagneticsensingtechnologiesthathelpsavoidunnecessaryradioactivityforbreastcancer~40Note(s):AI:Arti?cialIntelligence;SaaS:Software-as-a-service;4-D:4-dimensionalSource(s):Tracxn,Companywebsite(s),PGALabsanalysisFocusedonbreastcancer?PGALabs|1511Recentinnovations心心RecentinnovationsinBreastCancerdetection:Niramai(India)andVayyar(Israel)haveleveragedtechnicaladvancementstofacilitateearlydetectionFounded2016GeethaManjunathFounder&CEO25+yearsinIT&innovationEx-XeroxResearchIndia,HewlettPackardIndiaNiramaihasNiramaihas27grantedpatentsacrossdifferentcountries,with11ofthemgrantedintheUSand11oftheminIndia.?NIRAMAIhasdevelopedanovelsoftware-basedmedicaldevicetodetectbreastcanceratamuchearlierstagethantraditionalmethodsorself-examination?Radiationfreeimagingmethod,non-touch,notpainfulandworksforwomenofallages?Lowcost,accurate,automated,portablecancerscreeningtoolthatcanbeoperatedinanyclinicorfromhomeOverviewNote(s):AI:Arti?cialIntelligence;SaaS:Software-as-a-service;4-D:4-dimensionalSource(s):Tracxn,Companywebsite(s),PGALabsanalysisGeographicalPresenceIndiaUSAEuropeAXILR??Thermalytix:AcomputeraidedbreastcancerdetectionsystempoweredbyAI?XraySetu:AnAI-drivenX-rayanalysisforCOVIDinterpretationviaWhatsapp?NiramaiFeverTest:SimplescreeningforCOVIDsymptomsOfferings?PGALabs|1622Recentinnovations心心RecentinnovationsinBreastCancerdetection:Niramai(India)andVayyar(Israel)haveleveragedtechnicaladvancementstofacilitateearlydetectionFounded2011RavivMelamedCEOandCo-Founder22+yearsintechnologyEx-VicePresident,IntelArchitectureGroupMiriRatnerVPR&DandCo-Founder29+yearsinR&DEx–Director,RamlanLtdVayyarVayyarhas?ledforatotalof80patents,andhasbeengranted68patentstilldate.?VayyarImagingLtd.isasemiconductorcompanythatproduces4Dimagingradarsensors?Vayyar’sRadar-on-Chiptechnologywasdevelopedtoprovideamoreeffectivemeansofscreeningforearly-stagebreastcancer?Thecompany’ssensortechnologyisamoreaccessibleandeffectivealternativetomammogramsOverviewNote(s):AI:Arti?cialIntelligence;SaaS:Software-as-a-service;4-D:4-dimensionalSource(s):Tracxn,Companywebsite(s),PGALabsanalysisGeographicalPresenceIsraelUSAJapanChinaSwedenBattery??Radar-on-Chip:Provideshigh-resolution3Dimagesthatdetectbreastcancerwithpinpointaccuracy?VayyarCare:IncollaborationwithAlexa,itdetectsfallsinsecondstosaveoldpeople’slivesOfferings?PGALabs|17Cancercare心心Somenewandemergingcancercaremodelsrevolvearoundpersonalizingcancercareandmakingcancercaremorecompassionate,affordableandaccessible ModelIllustrativeexamplesParticularsTreatmentwork?owmanagementSharedexpertiseAffordabilityAZRAPersonalisedcancercare?Accesstohighqualityremoteexpertcare(viatelemedicineetc.)Treatmentwork?owmanagementSharedexpertiseAffordabilityAZRAPersonalisedcancercare?Preventionofpatientin?owtometrocities;localizingcancercare?Performanceimprovementsforthedeliveryofhigh-valuecancercareManagedcancercare?Accesstodedicatedcancercaremanagertohand-holdthroughthecancer-journeyi.e.,fromManagedcancercare?Relativelyaffordableradiationtherapyequipmentandsmallerfootprintto?tintoCobaltmachinebunkers?CollaborationswithbothcentralandstategovernmentstohelpclosethegapintheradiationtherapyinfrastructurethroughinitiativeslikePPP(publicprivatepartnership)projects?Trainingandskilldevelopmentprogramstoaddressgapofskilledmanpowerinradiotherapy?UsingArti?cialintelligence(AI)tomakecancercaremoreaccessibleandaccurate?Enhancedclinicaldecision-makingandimprovementindiagnosisandmedicaloutcomes?Advancedgenomicsandnext-gendigitalhealthtechnologyforsuperiorinsights?Optimaltreatmentoutcomesthroughpredictionsofpatienttherapyresponses;enablingtherapyselectionHomecare?Qualityhomecancercareviadoctor-driventreatment,hospital-likeclinicalaudits,e-monitoringcapabilities,andcustomizedtrainingtostaffHomecareEmergingstart-upsinIndiaforqualitycancercareSource(s):SecondaryResearch,PGALabsanalysis?PGALabs|18Distributors/?VendorFeedbackSurvey&NPS?VendorPerformanceBenchmarkingandConsolidation?VendorIdenti?cation,AssessmentandCost-Benchmarking?ScoringagainstPGALabsvendorbenchmarkingtoolkit?Costcomponentsvscompetition&industrystandard?ChannelNPS?Splitbetweenonline&of?ineetc?Channelmarginstructurevscompetition?GeographicalDistributors/?VendorFeedbackSurvey&NPS?VendorPerformanceBenchmarkingandConsolidation?VendorIdenti?cation,AssessmentandCost-Benchmarking?ScoringagainstPGALabsvendorbenchmarkingtoolkit?Costcomponentsvscompetition&industrystandard?ChannelNPS?Splitbetweenonline&of?ineetc?Channelmarginstructurevscompetition?Geographicalpenetrationvscompetition?Incentives/schemesworkingwell?Divers/barrierstoexpansion?Channeltradingterms?NPSscore&referralrate?Customersegmentsunsatis?ed&risktobrand?Driversforcustomerloyalty&NPS,ClientvsCompetition?DigitaltechnologyplaytoimproveNPS?Latent&unmetneedsofcustomers?Gapsincustomerexp.vsexpectation?TAM&SAMforecast?Cust.segmentation?Replacementdemand?Numberofplayersbyproductcategory,customersegments,geographyetc.?Growthdrives&opportunities?Anywhitespaces?Key